Related Experiment Video
Updated: Jun 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
The management of renovascular disease: ASTRAL and beyond
Ching M Cheung1, Constantina Chrysochou, Philip A Kalra
1Renal Department, Salford Royal Hospital, Stott Lane, Salford, Greater Manchester, UK.
Insights
Optimal medical management is key for atheromatous renovascular disease (ARVD). Revascularization benefits are unclear, and future research should identify suitable candidates for this treatment.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Vascular Surgery
Background:
- Atheromatous renovascular disease (ARVD) affects kidney function due to arterial narrowing.
- Recent advances in understanding ARVD pathophysiology and epidemiology have emerged.
Purpose of the Study:
- To review new findings in atheromatous renovascular disease (ARVD) literature since 2009.
- To analyze the impact of recent randomized controlled trials on ARVD management.
Main Methods:
- Literature review of ARVD studies published from 2009 onwards.
- Analysis of data from two major randomized controlled trials.
Main Results:
- Epidemiological data on ARVD has been updated.
- Randomized controlled trials show limited benefits of revascularization.
- Improved understanding of ischemic kidney pathophysiology.
- Advances in imaging for selecting patients for revascularization.
Conclusions:
- Optimal medical management is the primary treatment for ARVD.
- Renal revascularization is not the cornerstone of ARVD therapy.
- Further research is needed to identify patients who will benefit from revascularization.
Purpose Of Review:
This review concentrates on the new findings published in the atheromatous renovascular disease (ARVD) literature since the beginning of 2009, a period in which the results of two randomized control trials have been released.
Recent Findings:
The key advances have arisen with respect to the epidemiology of ARVD, the effects of revascularization as demonstrated by the results of randomized controlled trials, an understanding of the pathophysiology of the ischaemic kidney, and also there have been further insights regarding the selection of patients for revascularization utilizing structural and functional imaging.
Summary:
Optimal medical management (and not revascularization therapy) is the established cornerstone for all patients with ARVD. Future studies should be directed to identifying individuals who will significantly benefit from renal revascularization.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Hypertension V: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury VI: Nursing Management
